System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Franca Fagioli is an expert in Hematology at Ospedale Regina Margherita (Italy). As of October 2026, ScienceLeadR ranks Franca Fagioli in the top 1% of experts worldwide for Stem Cell Transplantation, Graft vs Host Disease and Cell Transplantation. Franca Fagioli has authored 676 publications, the most recent in 2026, and is an investigator in 59 clinical trials, 25 of them ongoing. SLR score: 2,927 (community average: 125). How the SLR is computed.

LeadR Profile

Franca Fagioli Ospedale Regina Margherita Italy
2 927 ScienceLeadR Reputation 2927

Unlock

Register Login
Network Map

Hematology

Subspecialties: Transplantation - Oncology - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1984 - 2026
Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 676

Citations

Citations: 20 344 1st author: 25 Last author: 196 Unique author: 1

Main journals

Blood 76
Bone Marrow Transplant 46
Pediatr Blood Cancer 30
Haematologica 29
J Clin Oncol 24

Best Journals

J Clin Oncol 13
N Engl J Med 6
Ann Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.
PMID 42631537 — mortality, incidence, leukemia, transplants, conditioning, psychological, transplantation, haploidentical, transplantation		Am J Hematol20260
Paediatric biobanking in the era of precision medicine: ethical, regulatory, and scientific challenges from childhood to adulthood.
PMID 42837009 — rare diseases, precision medicine, research, pediatrics		Eur J Pediatr20260
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
PMID 42748428 — cells, precursor cell lymphoblastic leukemia-lymphoma, disease-free survival, leukemia, drug therapy, therapeutics, random allocation, b-lymphocytes, child, chemotherapy		N Engl J Med Top journal20262
Narrative Matters: Drawing the diagnosis - shaping the truth in communicating acute lymphoblastic leukaemia in paediatric oncology.
PMID 42733287 — communication, psychoanalysis, diagnosis, child		Child Adolesc Ment Health20260
Psychological Processes in Adolescents Receiving Palliative Oncology Care: Clinical Implications for Multidisciplinary Teams.
PMID 42709469 — psychological phenomena, clinical decision-making, transference, psychology, adolescent		J Adolesc Young Adult Oncol20260

Clinical Studies 59

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7 Study Chair: 1

By phase:

Phase 3 16
Phase 1/Phase 2 15
N/A 13
Phase 2 10
Phase 2/Phase 3 4
Phase 1 1

By status:

Recruiting 28
Completed 16
Active not recruiting 6
Unknown 5
Terminated 2
Not yet recruiting 1
Suspended 1

By type:

Interventional 47
Observational 12

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 3
multicentricup10 48

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

25 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK 9999 01D)
2025-522339-32-00 — safety, neoplasms		Phase 1/Phase 2Recruiting2026
SIOP HRMB An international prospective trial on clinically high risk medulloblastoma (HR MB) in patients older than 3 years
2024-510578-25-00 — radiotherapy, medulloblastoma, therapeutics		Phase 3Recruiting2021
Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid refractory acute graft versus host disease
2023-503952-28-00 — cells, safety, microscopy, electron, scanning transmission, stem cells, mesenchymal stem cells, graft vs host disease, transplants, therapeutics, stromal cells, cell transplantation, stem cell transplantation, steroids, transplantation		Phase 2Active not recruiting2023
Tumor Agnostic Precision Immuno Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
2023-507418-28-00 — neoplasms		Phase 2Active not recruiting2021
Phase III Clinical Trial for CPX 351 in Myeloid Leukemia in Children with Down Syndrome 2018
2022-501457-37-00 — down syndrome, leukemia, leukemia, myeloid, child		Phase 3Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS